Two inhibitors of the HIV-1 integrase enzyme (INIs) are in late stage clinical development. To date, approximately 42 mutations within the HIV-1 integrase (IN) gene have been associated with INI drug resistance. Naturally occurring IN gene polymorphisms may have important implications for INI development. In this study, we evaluated clinical HIV-1 strains from INI-naive patients to determine the prevalence of IN gene polymorphisms, and the frequency of naturally occurring amino acid (aa) substitutions at positions associated with INI resistance and at sites crucial for LEDGF/p75 binding and HIV-1 integration.
Methods
The IN gene from 67 INI-naive, HIV-1 clade B-infected patients were sequenced using standard population-based DNA sequencing methods. In addition, 176 unique full-length HIV-1 clade B IN gene sequences from INI-naive patients obtained from the HIV Los Alamos database were analysed.
Results
Analysis of 243 IN genes from HIV-1 clade B, INI-naive clinical strains revealed that 64% of the aa positions were polymorphic. Of the 42 aa substitutions currently associated with INI resistance, 21 occurred as natural polymorphisms: V72I, L74I, T97A, T112I, A128T, E138K, Q148H, V151I, S153Y/A, M154I, N155H, K156N, E157Q, G163R, V165I, V201I, I203M, T206S, S230N and R263K. IN aa positions crucial to LEDGF/P75 binding and HIV-1 integration were well conserved.
Conclusion
Major INI mutations within the catalytic domain and extended active sites associated with high level resistance to the compounds in late stage development, especially strand transfer inhibitors (STIs), were infrequent in our study, which may help explain the excellent virological responses demonstrated in clinical trials.
References
1.
PommierY., JohnsonA.A., MarchandC.Integrase inhibitors to treat HIV/AIDS.Nat Rev Drug Discov2005; 4: 236–248.
2.
LatailladeM., KozalM.J.The hunt for HIV-1 integrase inhibitors.AIDS Patient Care STDS2006; 7: 489–501.
3.
Van MaeleB., DebyserZ.HIV-1 integration: an interplay between HIV-1 integrase, cellular and viral Proteins.AIDS Rev2005; 7: 26–43.
4.
GroblerJ.A., StillmockK., HuB.Diketo acid inhibitor mechanism and HIV-1 integrase: implications for metal binding in the active site of phosphotransferase enzymes.Proc Natl Acad Sci U S A2002; 99: 6661–6666.
5.
HazudaD.J.Inhibitors of human immunodeficiency virus type I.Retrovirology2006; 3Suppl 1: S7.
6.
DebyserZ., HombrouckA., WitvrouwM., De RijckJ., HendrixJ.Virus evolution reveals LEDGF/p75 as the sole mediator of chromosomal tethering.14th Conference on Retroviral and Opportunistic Infections 2007, Los Angeles CA, USA. Feb 25–28; Abs. 15.
7.
HombrouckA., De RijckJ., BusschotsK., Christ F DebyserZ.Structure-function analysis of the interface between HIV-1 integrase and the cellular co-factor LEDGF/p75.14th Conference on Retroviral and Opportunistic Infections2007, Los Angeles CA, USA. Feb 25–28; Abs. 189.
8.
CooperD., GatellJ., RockstrohJ., KatlamaC., IsaacsR., NguyenB.Results of BENCHMRK-1, a Phase III study evaluating the efficacy and safety of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus.14th Conference on Retroviral and Opportunistic Infections. 25–28 February 2007, Los Angeles CA, USA. Abs. 105aLB.
9.
SteigbigelR., KumarP., EronJ.Results of BENCHMRK-2, a Phase III study evaluating the efficacy and safety of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus.14th Conference on Retroviral and Opportunistic Infections. 25–28 February 2007, Los Angeles CA, USA. Abs. 105bLB.
10.
ZolopaA.R., MullenM., BergerD., RuaneP., HawkinsT.The HIV integrase inhibitor GS-9137 demonstrates potent anti-retroviral activity in treatment-experienced patients.14th Conference on Retroviral and Opportunistic Infections. 25–28 February 2007, Los Angeles CA, USA. Abs. 143LB.
11.
LatailladeM., ChiarellaJ., KozalM.J.. Natural polymorphism of the HIV-1 integrase gene and mutations associated with integrase inhibitor resistance.Antivir Ther2006; 11: S28.
12.
LlanoM., VanegasM., HutchinsN., ThompsonD., DelgadoS., PoeschlaE.M.Identification and characterization of the chromatin-binding domains of the HIV-1 integrase inter-actor LEDGF/p75.J Mol Biol2006; 360: 760–773.
13.
CherepanovP., AmbrosioA.L., RahmanS., EllenbergerT., EngelmanA.Structural basis for the recognition between HIV-1 integrase and transcriptional coactivator p75.Proc Natl Acad Sci U S A.2005; 102: 17308–17313.
WitvrouwM., HantsonA., HombrouckA.Multiple mutations in HIV-1 integrase confer resistance to the PyranoDipyrimidine V-165.5th HIV DRP Symposium on Antiretroviral Drug Resistance, 14–17 November 2004 Chantilly, VA, USA. Abstract # 18.
16.
PannecouqueC., PluymersW., Van MaeleB.New class of HIV integrase inhibitors that block viral replication in cell culture.Curr Biol2002; 12: 1169–1177.
17.
HazudaD.J., FelockP., WitmerM.Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells.Science2000; 287: 646–650.
18.
DayamR., Al-MawsawiL.Q., NeamatiN.HIV-1 integrase inhibitors: an emerging clinical reality.Drugs R D2007; 8: 155–168.
19.
HazudaD.J., AnthonyN.J., GomezR.P.A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase.Proc Natl Acad Sci U S A2004; 101: 11233–11238.
20.
KodamaE., ShimuraK., SakagamiY.In vitro antiviral activity and resistance profile of a novel HIV integrase inhibitor JTK-303/GS-9137.46th Interscience Conference on Antimicrobial Agents and Chemotherapy September 27–30, 2006, San Francisco, CA, USA. Abstract H-254.
21.
GrinsztejnB., NguyenB.Y., KatlamaC.Potent antiretroviral effect of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus.46th Interscience Conference on Antimicrobial Agents and Chemotherapy September 27–30 2006, San Francisco CA, USA. Abstract H1670b.
22.
BonnenfantS., ThomasC.M., VitaC.Styrylquinolines, integrase inhibitors acting prior to integration: a new mechanism of action for anti-integrase agents.J Virol2004; 78: 5728–5736.
23.
MousnierA., LehH., MouscadetJ.F., DargemontC.Nuclear import of HIV-1 integrase is inhibited in vitro by styrylquino-line derivatives.Mol Pharmacol2004; 66: 783–788.
24.
Di SantoR., CostiR., RouxA.Novel bifunctional quinolonyl diketo acid derivatives as HIV-1 integrase inhibitors: design, synthesis, biological activities, and mechanism of action.J Med Chem2006; 49: 1939–1945.
25.
MarchandC., JohnsonA.A., KarkiR.G.Metal-dependent inhibition of HIV-1 integrase by beta-diketo acids and resistance of the soluble double-mutant (F185K/C280S).Mol Pharmacol2003; 64: 600–609.
26.
LeeD.J., RobinsonW.E.Jr.Human immunodeficiency virus type 1 (HIV-1) integrase: resistance to DKA integrase inhibitors impairs HIV replication and integration and confers cross resistance to L-chicoric acid.J Virol, 2004; 78: 5835–5847.
27.
BarrecaM.L., LeeK.W., ChimirriA., BriggsJ.M.Molecular dynamics of the wild type and double mutant HIV-1 integrase complexed with 5-CITEP inhibitor: mechanism for inhibition and drug resistance.Biophys J2003; 84: 1450–1463.
28.
JohnsonV.A., Brun-VezinetF., ClotetB.Update of the drug resistance mutations in HIV-1: 2005.Top HIV Med2005; 13: 51–57.
29.
KozalM.J., ShahN., ShenN.Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays.Nat Med1996; 2: 753–759.
30.
De MeyerS., HillA., De BaereI.Effect of baseline susceptibility and on-treatment mutations on TMC114 and control PI efficacy: preliminary analysis of data from PI-experienced patients from POWER 1 and POWER 2.13th Conference on Retroviral and Opportunistic Infections2006, Denver, CO, USA. Abstract #157.
31.
KozalM.J., Huppler HullsiekK., LeducR.Prevalence and impact of HIV-1 protease codon 33 mutations and polymorphisms in treatment-naïve and treatment-experienced patients enrolling in clinical trials.Antivir Ther2006; 11: 457–463.
32.
FikkertV., Van MaeleB., VercammenJ., HantsonA., Van RemoortelB., MichielsM.Development of resistance against diketo derivatives of human immunodeficiency virus type 1 by progressive accumulation of integrase mutations.J Virol2003; 77: 11459–11470.
33.
FikkertV., HombroukA., Van RemoortelB.Multiple mutations in HIV-1 IN confer resistance to the clinical trial drug S-1360.AIDS2004; 18: 2019–2028.
34.
JonesG., LedfordR., YuF., MillerM., TsiangM., McCollD.Resistance Profile of HIV-1 Mutants in vitro Selected by the HIV-1 Integrase Inhibitor, GS-9137 (JTK-303).14th Conference on Retroviral and Opportunistic Infections. 25–28 February 2007, Los Angeles CA, USA. Abstract 627.
35.
WaiJ., FisherT., EmbreyM.Next generation of inhibitors of HIV-1 integrase strand transfer inhibitor: structural diversity and resistance profiles.14th Conference on Retroviral and Opportunistic Infections 25–28 February 2007, Los Angeles CA, USA. Abstract 87.
36.
HackettJ.Jr., SwansonP., HarrisB., HolzmayerV., YamaguchiJ., BodelleP., BrennanC., SchochetmanG., and DevareS.Comprehensive evaluation of HIV-1 integrase gene diversity in group M, N, and O viruses.12th Conference on Retroviral and Opportunistic Infections, 22–25 February 2005, Boston MA, USA. Abstract LB#366.
37.
ZioniR., RheeS., LiuT., ShaferR.Natural variation of HIV-1 group M integrase: implications for integrase inhibitor therapy.14th Conference on Retroviral and Opportunistic Infections 25–28 February 2007, Los Angeles CA, USA. Abstract 623.
38.
LuR., LimonA., GhoryH.Z., EngelmanA.Genetic analyses of DNA-binding mutants in the catalytic core domain of human immunodeficiency virus type 1 integrase.J Virol2005; 79: 2493–2505.
39.
LlanoM., SaenzD.T., MeehanA.An essential role for LEDGF/p75 in HIV integration.Science2006; 314: 461–464.
40.
EmilianiS., MousnierA., BusschotsK., MarounM., Van MaeleB., TempeD.Integrase mutants defective for interaction with LEDGF/p75 are impaired in chromosome tethering and HIV 1 replication.J Biol Chem2005; 280: 25517–25523.
